Search

Your search keyword '"Moras D"' showing total 758 results

Search Constraints

Start Over You searched for: Author "Moras D" Remove constraint Author: "Moras D"
758 results on '"Moras D"'

Search Results

401. Crystallization and preliminary X-ray crystallographic study of the wild type and two mutants of the CP1 hydrolytic domain from Aquifex aeolicus leucyl-tRNA synthetase.

402. Cloning, purification and crystallization of a Walker-type Pyrococcus abyssi ATPase family member.

403. Construction of a set Gateway-based destination vectors for high-throughput cloning and expression screening in Escherichia coli.

404. MAO: a Multiple Alignment Ontology for nucleic acid and protein sequences.

405. Solution structure of the C-terminal domain of TFIIH P44 subunit reveals a novel type of C4C4 ring domain involved in protein-protein interactions.

406. Structural basis for the cell-specific activities of the NGFI-B and the Nurr1 ligand-binding domain.

407. Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction.

408. Translational operator of mRNA on the ribosome: how repressor proteins exclude ribosome binding.

409. Binding of estrogenic compounds to recombinant estrogen receptor-alpha: application to environmental analysis.

410. Biochemical and NMR mapping of the interface between CREB-binding protein and ligand binding domains of nuclear receptor: beyond the LXXLL motif.

411. Structural genomics of eukaryotic targets at a laboratory scale.

412. Ligand-binding pocket of the ecdysone receptor.

413. Monitoring ligand-mediated nuclear receptor-coregulator interactions by noncovalent mass spectrometry.

414. Domain architecture of the p62 subunit from the human transcription/repair factor TFIIH deduced by limited proteolysis and mass spectrometry analysis.

415. Achieving error-free translation; the mechanism of proofreading of threonyl-tRNA synthetase at atomic resolution.

416. RARbeta ligand-binding domain bound to an SRC-1 co-activator peptide: purification, crystallization and preliminary X-ray diffraction analysis.

417. Translationally controlled tumor protein is a target of tumor reversion.

418. Identification of an alternative ligand-binding pocket in the nuclear vitamin D receptor and its functional importance in 1alpha,25(OH)2-vitamin D3 signaling.

419. Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity.

420. Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 A.

421. Structural investigation of the ligand binding domain of the zebrafish VDR in complexes with 1alpha,25(OH)2D3 and Gemini: purification, crystallization and preliminary X-ray diffraction analysis.

422. Signature of the oligomeric behaviour of nuclear receptors at the sequence and structural level.

423. Translationally controlled tumor protein acts as a guanine nucleotide dissociation inhibitor on the translation elongation factor eEF1A.

424. Structural adaptability in the ligand-binding pocket of the ecdysone hormone receptor.

425. ATP-bound conformation of topoisomerase IV: a possible target for quinolones in Streptococcus pneumoniae.

426. All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR beta.

427. Conformational movements and cooperativity upon amino acid, ATP and tRNA binding in threonyl-tRNA synthetase.

428. Using nondenaturing mass spectrometry to detect fortuitous ligands in orphan nuclear receptors.

429. The dual role of CHAPS in the crystallization of stromelysin-3 catalytic domain.

430. Interaction between vitamin D receptor and vitamin D ligands: two-dimensional alanine scanning mutational analysis.

431. The NF-YB/NF-YC structure gives insight into DNA binding and transcription regulation by CCAAT factor NF-Y.

432. Structure-activity relationship of nuclear receptor-ligand interactions.

433. Comparative analysis of ribosomal proteins in complete genomes: an example of reductive evolution at the domain scale.

434. Crystal structure of a subcomplex of human transcription factor TFIID formed by TATA binding protein-associated factors hTAF4 (hTAF(II)135) and hTAF12 (hTAF(II)20).

435. C-H...O hydrogen bonds in the nuclear receptor RARgamma--a potential tool for drug selectivity.

436. p52 Mediates XPB function within the transcription/repair factor TFIIH.

437. DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5'-methyl group of the noviose.

438. An open conformation of the Thermus thermophilus gyrase B ATP-binding domain.

439. Molecular recognition of agonist ligands by RXRs.

440. Structural basis of translational control by Escherichia coli threonyl tRNA synthetase.

441. Crystal structure of the V-region of Streptococcus mutans antigen I/II at 2.4 A resolution suggests a sugar preformed binding site.

442. Expression of FLAG fusion proteins in insect cells: application to the multi-subunit transcription/DNA repair factor TFIIH.

443. NF-Y recruitment of TFIID, multiple interactions with histone fold TAF(II)s.

444. Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3.

445. Structure-based analysis of the ultraspiracle protein and docking studies of putative ligands.

446. X-ray structure of the orphan nuclear receptor RORbeta ligand-binding domain in the active conformation.

447. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.

448. The structure of an AspRS-tRNA(Asp) complex reveals a tRNA-dependent control mechanism.

449. Overexpression, purification, and crystal structure of native ER alpha LBD.

450. Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism.

Catalog

Books, media, physical & digital resources